Carrington Laboratories Inc. of Irving, Texas, said that threeindependent directors found no evidence of impropriety byClinton Howard, the company's former president and chiefexecutive, who was forced last October to sell 855,000Carrington shares to meet brokerage margin calls.Carrington's stock (NASDAQ:CARN) price fell and Howardresigned.

Carrington posted a $6.1 million loss, or 98 cents a share, forthe year ended last Nov. 30. The loss reflected a write-off ofwork connected with a canceled production facility for thecompany's drug, Carrisyn. -- Rachel Nowak

(c) 1997 American Health Consultants. All rights reserved.